Metformin - The gold standard in type 2 diabetes: What does the evidence tell us?

Diabetes, Obesity and Metabolism

Volumn 11, Issue SUPPL. 2, 2009, Pages 3-8

  Bosi, Emanuele ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Combination therapy; Glycated haemoglobin; Incretin; Metformin

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; CHLORPROPAMIDE; GLIBENCLAMIDE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SULFONYLUREA;

ABDOMINAL PAIN; ANOREXIA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIABETIC DIET; DIARRHEA; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FRACTURE; GASTROINTESTINAL DISEASE; GLYCEMIC CONTROL; HUMAN; HYPERINSULINEMIA; HYPOGLYCEMIA; LACTIC ACIDOSIS; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; RISK REDUCTION; SIDE EFFECT; TASTE DISORDER; WEIGHT GAIN;

EID: 65449133147     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2008.01031.x     Document Type: Review

References (18)

1. Riddle MC. Glycemic management of type 2 diabetes: An emerging strategy with oral agents, insulins, and combinations. Endocrinol Metab Clin North Am 2005; 34: 77-98.
2. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29: 1963-1972.
3. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: A consensus statement of the American Diabetes Association and the European Association for the study of Diabetes. Diabetes Care 2009; 32: 193-205.
4. Zhou G, Myers R, Li Y et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001; 108: 1167-1174.
5. Stumvoll M, Häring H-U, Matthaei S. Metformin. Endocr Res 2007; 32: 39-57.
6. Marchetti P, Del Guerra S, Marselli L et al. Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J Clin Endocrinol Metab 2004; 89: 5535-5541.
7. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: Results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997; 102: 491-497.
8. Grant PJ. The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabetes Care 1996; 19: 64-66.
9. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects: A study of two ethnic groups. Diabetes Care 1993; 16: 621-629.
10. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
11. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
12. WulffeléMG, Kooy A, De Zeeuw D, Stehouwer CDA, Gansevoort RT. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: A systematic review. J Intern Med 2004; 256: 1-14.
13. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334: 574-579.
14. Holstein A, Stumvoll M. Contraindications can damage your health - is metformin a case in point? Diabetologia 2005; 48: 2454-2459.
15. Kimmel B, Inzucchi SE. Oral agents for type 2 diabetes: An update. Clin Diabetes 2005; 23: 64-76.
16. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes. Scientific review. JAMA 2002; 287: 360-372.
17. Dormandy J, Charbonnel B, Eckland DJA et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.
18. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007; 30: 890-895.